FDA Approves Amgen's Panitumumab to Treat Advanced Colon Cancer

Publication
Article
OncologyONCOLOGY Vol 20 No 11
Volume 20
Issue 11

Following priority review, the US Food and Drug Administration (FDA) has approved Amgen Inc's panitumumab (Vectibix) for the treatment of advanced colon cancer.

Following priority review, the US Food and Drug Administration (FDA) has approved Amgen Inc's panitumumab (Vectibix) for the treatment of advanced colon cancer. The drug is the first entirely human monoclonal antibody for the treatment of patients with epidermal growth factor receptor-expressing metastatic colorectal cancer after disease progression on or following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.

Better-Than-Expected Results

Panitumumab received an accelerated approval after showing effectiveness in slowing tumor growth and, in some cases, reducing the size of the tumor, the FDA said in a statement. The approval was based on a progression-free survival endpoint. A pivotal trial also showed that patients treated with panitumumab showed a better-than-expected 46% decrease in the rate of tumor growth vs those who received supportive care.

As part of the approval, Amgen committed to conduct a postmarketing trial to show whether the drug improves patients' survival in patients with fewer prior chemotherapies, the FDA said.

Recent Videos
Prolonging systemic therapy in patients with gastric or gastroesophageal junction cancers may offer better outcomes than radiation therapy.
Advances in perioperative targeted therapies may enable organ preservation and significantly enhance outcomes for patients with gastric cancers.
Combining sotorasib with panitumumab may reduce the burden of disease in patients with KRAS G12C-mutated metastatic colorectal cancer.
Findings from the CodeBreak 300 study have cemented sotorasib/panitumumab as a third-line treatment option for KRAS G12C-mutated colorectal cancer.
Sotorasib plus panitumumab may offer improved survival compared with previously approved treatment options in KRAS G12C-mutated colorectal cancer.
Additional local, regional, or national policy may bolster access to screening for colorectal cancer, according to Aasma Shaukat, MD, MPH.
The mechanism of action for daraxonrasib inhibits effectors and signaling while forming a relatively unstable tri-complex with codon 12 mutations.
Related Content